XHKG
0897
Market cap53mUSD
Oct 08, Last price
0.38HKD
1D
0.00%
1Q
31.03%
Jan 2017
0.00%
Name
Wai Yuen Tong Medicine Holdings Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Wai Yuen Tong Medicine Holdings Limited operates as an investment holding company with a multifaceted business portfolio. Its core activities encompass the production, processing, and retail distribution of traditional Chinese medicines, Western pharmaceuticals, and a range of health and personal care products. These offerings reach customers across Hong Kong, mainland China, Macau, and international markets. The company's Chinese medicine and health food lines are marketed under the Wai Yuen Tong brand, while its Western pharmaceutical and personal care items are available under the Madame Pearl's and Pearl's labels. Beyond its product-focused segments, the group also engages in property investment, ownership, and sales, provides financial services, and oversees an agricultural produce exchange. As of March 31, 2022, Wai Yuen Tong maintained 63 retail stores in Hong Kong. Founded in 1897, the company is headquartered in Kowloon Bay, Hong Kong, and operates as a subsidiary of Rich Time Strategy Limited.
Key people
Ching Ho Tang
Executive Chairman of the Board, Managing Director · since 2018
Seung Ming Wong
Financial Controller · since 2022
Man Yee Law
Executive Director · since 2021
Wai Man Tang
Executive Director · since 2018
Siu Fai Chan
Head of Factory Operations
Kam Wing Mak
General Manager - Luxembourg Medicine Group · since 2022
Yuen Wo Tsang
Director - Technical · since 2018
Company Secretary · since 2024
Wing Kwong Chan
Independent Non-Executive Director · since 2023
Independent Non-Executive Director · since 2015
Independent Non-Executive Director · since 2023
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||